SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec - Quaterly Results

14 Feb 2023 Evaluate
The topline surged 87.03% to Rs. 719.70 millions for the December 2022 quarter as against Rs. 384.80 millions during the corresponding quarter last year.The Total Profit for the quarter ended December 2022 of Rs. 132.40 millions grew from Rs.-224.30 millions Operating profit Margin for the quarter ended December 2022 improved to 220.00% as compared to -140.60% of corresponding quarter ended December 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 719.70 384.80 87.03 1820.50 1940.00 -6.16 2355.00 3435.60 -31.45
Other Income 97.10 23.80 307.98 241.60 100.00 141.60 125.70 207.40 -39.39
PBIDT 220.00 -140.60 -256.47 -418.90 -433.00 -3.26 -601.10 212.40 -383.00
Interest 26.80 19.10 40.31 73.60 56.00 31.43 70.40 75.20 -6.38
PBDT 193.20 -159.70 -220.98 -492.50 -489.00 0.72 -671.50 137.20 -589.43
Depreciation 60.80 64.60 -5.88 186.00 193.70 -3.98 264.30 265.70 -0.53
PBT 132.40 -224.30 -159.03 -678.50 -682.70 -0.62 -935.80 -128.50 628.25
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15.60 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -7.10 0.00
PAT 132.40 -224.30 -159.03 -678.50 -682.70 -0.62 -935.80 -144.10 549.41
Equity 61.30 61.30 0.00 61.30 61.30 0.00 61.30 61.30 0.00
PBIDTM(%) 30.57 -36.54 -183.66 -23.01 -22.32 3.09 -25.52 6.18 -512.86

Panacea Biotec Share Price

358.00 5.30 (1.50%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×